Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Slides:

Advertisements

Similar presentations

Approach to Acute Leukemia

Advertisements

Acute Myeloid Leukemia

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,

FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup by Jacques Delaunay, Norbert Vey, Thierry.

by James O. Armitage, and Dan L. Longo

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Gupta V, Tallman MS, Weisdorf DJ

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Long-term outcome after bone marrow transplantation for severe aplastic anemia by Lionel Ades, Jean-Yves Mary, Marie Robin, Christèle Ferry, Raphael Porcher,

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Tax fingerprint in adult T-cell leukemia

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

How I treat elderly patients with myeloma

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

by Achille Iolascon, Hermann Heimpel, Anders Wahlin, and Hannah Tamary

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Overall survival by SCT versus observation in first complete remission

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Treatment versus Transplant for Challenging Hematologic Disorders

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

How I treat refractory and early relapsed acute myeloid leukemia

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

by Jan J. Cornelissen, and Didier Blaise

Cold agglutinin disease

Presentation transcript:

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic, Åsa Derolf, Sören Lehmann, Lars Möllgård, Dick Stockelberg, Ulf Tidefelt, Anders Wahlin, and Martin Höglund Blood Volume 113(18):4179-4187 April 30, 2009 ©2009 by American Society of Hematology

Incidence of AML (non-APL) in 1997 to 2005 (new cases per 100 000 inhabitants, based on the Swedish population in 2005) according to age and sex. Incidence of AML (non-APL) in 1997 to 2005 (new cases per 100 000 inhabitants, based on the Swedish population in 2005) according to age and sex. Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Proportion of AML (non-APL) patients with WHO/ECOG performance status 0 to IV at diagnosis according to age. Proportion of AML (non-APL) patients with WHO/ECOG performance status 0 to IV at diagnosis according to age. The numbers of patients are given at the bottom of the figure. Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Early death rates (within 30 days from diagnosis) with intensive therapy according to age and performance status. Early death rates (within 30 days from diagnosis) with intensive therapy according to age and performance status. The numbers of patients are given in Table 1. Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Complete remission rates with intensive treatment according to age and WHO/ECOG performance status. Complete remission rates with intensive treatment according to age and WHO/ECOG performance status. The numbers of patients are given in Table 1. Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Overall survival according to age irrespective of management (top, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (bottom, n = 1229). Overall survival according to age irrespective of management (top, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (bottom, n = 1229). Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Overall survival according to WHO/ECOG performance status, only patients fit for intensive treatment. Overall survival according to WHO/ECOG performance status, only patients fit for intensive treatment. Patients younger than 65 years (top, n = 864) and 65 to 79 years (bottom, n = 711). Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology

Overall survival of all patients, treated and untreated, 70 to 79 years of age according to geographic region, with different proportions of patients given intensive therapy (Table 4). Overall survival of all patients, treated and untreated, 70 to 79 years of age according to geographic region, with different proportions of patients given intensive therapy (Table 4). Gunnar Juliusson et al. Blood 2009;113:4179-4187 ©2009 by American Society of Hematology